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BACKGROUND/INTRODUCTION

In December 2013, the U.S. Preventive Services Task Force issued a “B” rating for
lung cancer screening with low-dose CT scan in adults ages 55 to 80 with a 30
1
pack-year history and who continue to smoke or quit within the past 15 years.
Reimbursement guidelines from Medicare include documentation of shared decision2
making (SDM) with patients, though tools to facilitate decision support are limited.
Lung cancer screening has limited public awareness due to its relatively recent
recommendation.

OBJECTIVE

To create a lung cancer screening SDM tool and patient educational materials by a
Patient and Stakeholder Advisory Committee (PASAC).

METHODS
STUDY DESIGN

As part of the Reducing Cancer Disparities by Engaging Stakeholders (RCaDES)
Initiative, an iterative process was applied to facilitate the creation of patient
materials through regular convening of the PASAC and community testing.

PROCESS

DISCUSSION
MATERIAL
DEVELOPMENT

CURRICULUM

• Review of terms, pathways,
coverage requirements,
processes, literature

• Brainstorming – Patient needs

• Community testing and feedback
• Iterative revision process

• Review of current educational
and evidence-based SDM tools

• Brainstorming – Provider/
Network Needs
• Iterative mock-up process

• Presentation and recommendation
to Leadership

PRODUCT

• Draft final products

IS LUNG CANCER SCREENING RIGHT FOR ME?
Frequently
Asked
Questions
Who is it
offered to?

Screening using low dose CT

No Screening

High-risk smokers or ex-smokers:
• Aged 55 to 80
• Have smoked at least 1 pack a day for thirty years.
• No symptoms of lung cancer.
Ex-smokers are offered screening if they have quit in the last 15
years.

People who are not at high risk of
lung cancer are not offered
screening because there is no
proven benefit to them.

How is lung
cancer
found?

Using low-dose CT: an x-ray offered once a year.
This test takes a few minutes and needs no special preparation.

Without screening, lung cancer is
usually found after symptoms are
present or when other tests are done.
In these cases, lung cancer is more
likely to be found at a later stage.

A PASAC comprised of patients, community and health network stakeholders
including primary care and specialty clinicians and administrative representatives.

What are the
benefits of
screening?

Low-dose CT finds signs of possible lung cancer in roughly 1 in
every 100 screened at a time when treatment has a better chance
of success.
65 in every 100 scans will not find any problems.

Does not apply

METHODS

What are the
harms or
risks?

False alarms: Roughly 25 in every 100 people have small nodules
found in their lungs. To make sure these nodules are not cancer,
more tests are done, for up to 2 years.
Unnecessary treatment: Some suspicious nodules may be treated
even though they may never cause problems.
Finding more problems: Low-dose CT sometimes reveals findings
in other parts of the body. These may lead to more tests and
possible treatment.
Radiation: There is a small radiation risk of CT scans, in this case it
is similar to a dental x-ray

If are at risk and do not screen, you
might worry that you have missed a
chance to find the cancer early.
If cancer is found because of
symptoms (like unexplained weight
loss and coughing up blood) then the
cancer is probably more advanced,
and treatment will be more difficult.

25 people in every 100 screened will be told they have nodules, but
few of these will be cancer. More tests will probably be done.
Roughly 10 in every 100 people screened will be told about other
problems, such as infections or lung damage from smoking.

Does not apply

SETTING

Lehigh Valley Practice and Community- Based Research Network (LV-PBCRN), in
collaboration with Thomas Jefferson University, prime contractor.

PARTICIPANTS

The PASAC reviewed evidence-based literature and screening pathways and
developed a tool to facilitate SDM in the clinical encounter, as well as educational
material to be distributed to patients who may be eligible for screening. Each
committee member was asked to test materials with 10 other community members
for readability and feedback.

CONSENSUS

What are the
possible
results?

• Consensus of materials

• The PASAC chose the adoption of a standardized SDM tool (Option Grid™) and a
de novo patient education tool for incorporation into the developing lung cancer
screening program.
• The PASAC led the design, identification of core information, language and testing
of the de novo product.
• The PASAC presented final materials to network leadership as part of a lung
cancer screening program recommendation.

CONCLUSION

• Engaging patient and other stakeholders in the design of end-user educational
materials is critical in creating culturally appropriate and tailored messaging materials.
• Utilizing a PASAC to create and test materials for patient and clinician end-users
provides for low burden and exponential community feedback.

NEXT STEPS

Materials will be piloted in the clinical setting as part of a comprehensive lung cancer
screening and lung health program.
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